We target healthcare assets with significant clinical value and strong barriers to entry that are marketed by some of the world's largest pharmaceutical companies. We also look for assets that will produce sustainable revenues over an extended period of time. Our investments span the pharmaceutical, biotechnology, specialty pharmaceutical, and medical device/diagnostics sectors.
AndexXa (Andexanet Alfa), if approved, would be the first antidote available to reverse the anticoagulation effects of Factor Xa inhibitors (e.g., Xarelto, Eliquis, Savaysa). AndexXa was awarded FDA Breakthrough Designation and has been developed using the FDA's Accelerated Approval Pathway and Orphan Drug Designation.
Bellafill® is a highly differentiated dermal filler that provides immediate results and lasting improvement for patients. Approved by the FDA for the correction of wrinkles known as smile lines, Bellafill plumps wrinkles but also helps re-create the firmer structure of younger looking skin.
Biosense Webster Catheters
Biosense Webster is the market leader in the catheter ablation market. The Company has a full line of non-location sensing mapping and ablation catheters used to treat cardiac arrhythmias. Biosense Webster’s Celsius® RMT and NaviStar® RMT families of catheters, including the industry leading Celsius® and NaviStar® RMT ThermoCool® catheters, incorporate Stereotaxis’ Niobe® ES Remote Magnetic Navigation system for optimal performance and highly precise catheter manipulation.
|Marketer:||Biosense Webster, a Johnson & Johnson company|
Cetrotide® is a fertility drug commonly used in in-vitro fertilization procedures. The gonadotropin releasing hormone (GnRH) antagonist is used to prevent premature ovulation in controlled ovarian stimulation prior to assisted reproductive technologies (ART).
Coherus Biosciences is a leading pure-play, global biosimilars company. Coherus is advancing three late-stage clinical products towards commercialization, CHS-1701 (pegfilgrastim/ Neulasta biosimilar), CHS-0214 (etanercept/ Enbrel biosimilar) and CHS-1420 (adalimumab/ Humira biosimilar), which are currently in phase 3 or BLA-enabling trials.
Eigr Illumination Technology
Eigr™ is a new, patented breakthrough illumination technology that is designed to shape and deliver light deep into a surgical incision without shadows, glare or heat. The technology provides unsurpassed illumination and visualization which results in safer and more efficient surgeries for physicians.
ELIGARD® is a prescription drug used to manage the symptoms of advanced prostate cancer. Eligard is an LHRH (luteinizing hormone-releasing hormone) agonist and is designed to reduce the amount of testosterone in the body by reducing the testicles' production of testosterone.
|Marketer:||Astellas Pharma Europe|
Erivedge® (vismodegib) was approved in 2012 to treat symptomatic metastatic basal cell carcinoma or locally advanced BCC inappropriate for surgery or radiotherapy. Erivedge® was launched in 2012 in the U.S. and in 2016 the product generated over $200 million in worldwide net sales.
Inavir is the leading treatment for the treatment of influenza in Japan. It has a very favorable product profile due to its "one and done" dose form (e.g. disposable inhaler and single-dose treatment) as compared to other treatments which are required to be taken in multiple doses.
|Year Invested:||2013, 2016|
KAMRA™ inlay provides corrective treatment for presbyopia, or the natural loss of near vision (similar to farsightedness) that most people start experiencing in their 40s and 50s. The KAMRA inlay is an intra-corneal inlay designed to create a small aperture effect, allowing the eye to see near and intermediate objects more clearly while maintaining distance vision.
|Stage:||Commercially available in 50 countries. It is limited by federal (U.S.) law to investigational use and not available for sale in the United States.|
LEXIVA® (Telzir® in the European Union) is a protease inhibitor for the treatment of HIV/AIDS infection. The product has a strong long term safety profile and is currently approved for sale in approximately 45 countries. Lexiva was developed and commercialized under a license agreement between GlaxoSmithKline and Vertex Pharmaceuticals.
|Marketer:||ViiV Healthcare, a GlaxoSmithKline company|
Drug Discovery Licensing Platform
Dyax Corporation developed a proprietary drug discovery technology, phage display, to identify antibody, small protein and peptide compounds for clinical development. The company leverages this technology broadly through the Licensing and Funded Research Program (LFRP). The LFRP has over 70 revenue generating licenses and collaborations for therapeutic discovery, as well as in non-core areas such as affinity separations, diagnostic imaging, and research reagents. Two marketed products stem from this technology including Dyax’s KALBITOR® and Pfizer’s Xyntha® (solofuse).
|Year Invested:||2008, 2009, 2012|
TearScience is the first company to offer a device-based solution for the diagnosis and treatment of Evaporative Dry Eye Disease, a $10 billion market opportunity in North America. The TearScience system includes both a diagnostic device (LipiView) and a therapeutic device (LipiFlow) to enable ophthalmologists to treat the root cause of lipid deficient evaporative dry eye.
LYRICA® is Pfizer’s largest product and generates over $4 billion in sales annually. The oral small molecule drug was developed for the treatment of neuropathic pain. It treats two of the most common forms of nerve pain: diabetic peripheral neuropathy (“DPN”) and post-herpetic neuralgia (“PHN”), and is applicable to and indicated in a broad range of other disorders. Current indications include DPN, PHN, generalized anxiety disorder (“GAD”), neuropathic back pain, fibromyalgia and as an adjunctive therapy to other anti-seizure medications in treating partial seizures in epilepsy.
ORACEA® is a convenient, once-daily pill for the bumps and blemishes of rosacea. ORACEA is different because it treats inflammation below the skin, the true cause of rosacea. The active ingredient in ORACEA is doxycycline, but unlike traditional antibiotic doses of doxycycline, the low-dose formulation of ORACEA does not kill bacteria, it reduces the bumps and blemishes of rosacea because of its anti-inflammatory properties.
Orenitram™ is a prescription medicine used to treat pulmonary arterial hypertension (PAH) which is high blood pressure in the arteries of the lungs. It is the first and only FDA-approved oral prostacyclin class therapy in a tablet and represents a meaningful advance in the treatment of PAH.
|Marketer:||United Therapeutics Corporation|
PROCYSBI® is an orphan drug for the management of nephropathic cystinosis in adults and children 6 years and older. Nephropathic cystinosis is the most common form of cystinosis, a rare, inherited condition that affects every cell of the body by causing the buildup of a protein building block called cystine. PROCYSBI is a delayed-release form of cysteamine bitartrate that works by continuously reducing the toxic levels of cystine in the cells. It offers patients a more tolerable cystinosis treatment with a less burdensome dosing schedule.
Qutenza® is the first and only prescription-strength capsaicin product to treat post-shingles nerve pain also known as postherpetic neuralgia. Qutenza delivers medicine directly into the skin to the nerves that cause pain after shingles. A single, 1-hour application can provide up to three months of pain relief.
Regenica® is a skin care system with next generation growth factor technology. It is composed of three unique products, Replenishing Crème, Renew SPF15 and Repair Complex, each of which has the ability to improve the skin’s appearance and reduce signs of aging.
ReFissa® is the only FDA approved topical to treat skin texture. Its 0.05% tretinoin concentration provides the highest efficacy and lowest reaction threshold for the reduction of fine lines, wrinkles, hyperpigmentation, and tactile roughness. ReFissa is the only tretinoin product delivered in a soothing emollient cream that can be easily tolerated by all skin types - even dry or sensitive skin.
Relistor® is approved by the FDA to treat opioid-induced constipation ("OIC"), a long-lasting and potentially debilitating side effect of opioid therapy for millions of patients suffering from chronic pain. Relistor is the only drug approved for OIC in both palliative care and non-cancer pain patients and the product is now approved in both subcutaneous and oral formulations.
SUMAVEL® DosePro® (NOTE: For the marketer we are going to say “Exited” as they are no longer invested – there will be no roll over content)
Veltassa is the first new drug approved to treat hyperkalemia in over 50 years and the first drug approved to treat the management of chronic hyperkalemia. Hyperkalemia is a condition defined by abnormally elevated levels of potassium in the blood that is typically seen in patients with chronic kidney disease and heart failure and can result in severe medical complications.